The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CAPRA: Safety, efficacy, and translational biomarkers of weekly everolimus, carboplatin, and paclitaxel as induction therapy for locally advanced head and neck squamous cell carcinoma (HNSCC).
Eric Raymond
Consultant or Advisory Role - Novartis
Christophe Le Tourneau
No relevant relationships to disclose
Michel Gatineau
No relevant relationships to disclose
Jean-Pierre Delord
No relevant relationships to disclose
Jérôme Fayette
No relevant relationships to disclose
Chantal Dreyer
No relevant relationships to disclose
Annemilai Tijeras-Raballand
No relevant relationships to disclose
Sebastien Albert
No relevant relationships to disclose
Muriel Granier
No relevant relationships to disclose
Benoist Chibaudel
No relevant relationships to disclose
Alexandra Hadengue
No relevant relationships to disclose
Nasredine Aissat
No relevant relationships to disclose
Khemaies Slimane
Employment or Leadership Position - Novartis
Sandrine J. Faivre
Consultant or Advisory Role - Novartis